News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26,379 Results
Type
Article (4055)
Company Profile (4)
Press Release (22320)
Multimedia
Podcasts (37)
Webinars (4)
Section
Business (10007)
Career Advice (41)
Deals (1258)
Drug Delivery (28)
Drug Development (4566)
Employer Resources (12)
FDA (731)
Job Trends (1089)
News (15228)
Policy (1571)
Tag
2027 BioCapital Standard (2)
Academia (81)
Accelerated approval (3)
Adcomms (2)
Allergies (2)
Alliances (2277)
ALS (3)
Alzheimer's disease (42)
Antibody-drug conjugate (ADC) (131)
Approvals (748)
Artificial intelligence (36)
ASCO (66)
Autoimmune disease (17)
Automation (2)
Bankruptcy (9)
Best Places to Work (849)
BIO (1)
BIOSECURE Act (7)
Biosimilars (10)
BioSpace Insights (6)
Biotechnology (1)
Bispecific (1)
Bladder cancer (28)
Brain cancer (11)
Breast cancer (89)
Cancer (663)
Cardiovascular disease (48)
Career advice (48)
Career pathing (2)
CAR-T (14)
CDC (14)
CDMO (21)
Cell therapy (29)
Cervical cancer (8)
Clinical research (3934)
Collaboration (110)
Commercialization (2)
Company closure (4)
Compensation (7)
Complete response letters (7)
COVID-19 (209)
CRISPR (3)
C-suite (138)
Cystic fibrosis (3)
Data (310)
Depression (4)
Dermatology (3)
Diabetes (12)
Diagnostics (100)
Digital health (2)
Diversity, equity & inclusion (3)
Drug discovery (19)
Drug pricing (52)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (2367)
Editorial (11)
Employer branding (6)
Employer resources (12)
ESMO (52)
Events (2641)
Executive appointments (118)
Eye disease (1)
FDA (867)
Funding (76)
Gene editing (10)
Generative AI (3)
Gene therapy (17)
GLP-1 (85)
Government (343)
Grass and pollen (1)
Guidances (8)
Healthcare (485)
Hematology (8)
HIV (20)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (42)
Immuno-oncology (27)
Indications (18)
Infectious disease (242)
Inflammatory bowel disease (11)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (8)
Interviews (2)
IPO (382)
IRA (12)
Job creations (284)
Job search strategy (41)
JPM (9)
Kidney cancer (6)
Kidney disease (1)
Labor market (14)
Layoffs (72)
Leadership (4)
Legal (398)
Licensing (3)
Liver cancer (8)
Longevity (1)
Lung cancer (152)
Lung diease (1)
Lymphoma (16)
Machine learning (2)
Management (4)
Manufacturing (64)
MASH (8)
Medical device (79)
Medtech (79)
Mergers & acquisitions (922)
Metabolic disorders (62)
mRNA (49)
Multiple sclerosis (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (10)
Neuroscience (94)
NextGen: Class of 2026 (205)
Non-profit (99)
Now hiring (4)
Obesity (40)
Opinion (38)
Ovarian cancer (31)
Pain (6)
Pancreatic cancer (12)
Parkinson's disease (6)
Patents (29)
Patient recruitment (15)
Patient selection (2)
People (4211)
Peptides (1)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1118)
Phase 2 (1746)
Phase 3 (1655)
Pipeline (422)
Policy (65)
Postmarket research (206)
Preclinical (284)
Press Release (2)
Prostate cancer (7)
Psychedelics (10)
Radiopharmaceuticals (20)
Rare diseases (44)
Real estate (206)
Recruiting (4)
Regulatory (1161)
Reports (6)
Research institute (76)
Resumes & cover letters (1)
RNA editing (2)
RSV (18)
Schizophrenia (4)
Series A (19)
Series B (11)
Sickle cell disease (3)
Special edition (8)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (221)
Stomach cancer (10)
Supply chain (9)
Tariffs (23)
The Weekly (35)
Vaccines (179)
Venture capital (20)
Weight loss (34)
Women's health (6)
Worklife (2)
Date
Today (3)
Last 7 days (34)
Last 30 days (95)
Last 365 days (1023)
2026 (843)
2025 (1029)
2024 (1236)
2023 (1322)
2022 (2889)
2021 (2705)
2020 (2220)
2019 (1539)
2018 (1204)
2017 (1326)
2016 (1161)
2015 (1305)
2014 (868)
2013 (725)
2012 (794)
2011 (885)
2010 (818)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (3)
Asia (1649)
Australia (409)
California (314)
Canada (106)
China (147)
Colorado (6)
Connecticut (8)
Delaware (17)
Europe (4472)
Florida (79)
Georgia (3)
Illinois (14)
India (3)
Indiana (6)
Japan (78)
Kansas (1)
Kentucky (1)
Maryland (74)
Massachusetts (343)
Michigan (2)
Minnesota (6)
Mississippi (1)
Missouri (4)
Montana (1)
Nevada (2)
New Hampshire (5)
New Jersey (368)
New York (101)
North Carolina (27)
Northern California (173)
Ohio (3)
Oregon (1)
Pennsylvania (39)
Rhode Island (4)
South America (61)
South Carolina (1)
Southern California (110)
Tennessee (2)
Texas (33)
United States (1442)
Utah (9)
Virginia (10)
Washington D.C. (5)
Washington State (37)
West Virginia (1)
Wisconsin (4)
26,379 Results for "merck serono".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
September 24, 2026
·
2 min read
·
Annalee Armstrong
antibody-drug conjugate (ADC)
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.”
October 22, 2026
·
5 min read
·
Heather McKenzie
Cancer
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.
October 26, 2026
·
4 min read
·
Heather McKenzie
Lung cancer
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
September 3, 2026
·
2 min read
·
Annalee Armstrong
Drug Development
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
October 1, 2026
·
2 min read
·
Tristan Manalac
Press Releases
PostEra’s Fertility programs acquired by EMD Serono, Inc.
September 9, 2026
·
2 min read
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.
October 8, 2026
·
2 min read
·
Nick Paul Taylor
Vaccines
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.
October 5, 2026
·
2 min read
·
Annalee Armstrong
Business
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.
October 2, 2026
·
4 min read
·
Gabrielle Masson
Earnings
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations.
October 29, 2026
·
4 min read
·
Heather McKenzie
1 of 2,638
Next
